Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zogenix, Inc.    ZGNX

ZOGENIX, INC. (ZGNX)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
37.6(c) 35.15(c) 35.45(c) 35.3(c) 35.95(c) Last
905 759 1 422 011 424 753 412 281 513 945 Volume
+5.32% -6.52% +0.85% -0.42% +1.84% Change
More quotes
Financials ($)
Sales 2017 9,81 M
EBIT 2017 -110 M
Net income 2017 -111 M
Finance 2017 263 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -106 M
Net income 2018 -107 M
Finance 2018 13,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 88,8x
EV / Sales2018 0
Capitalization 1 134 M
More Financials
Company
Zogenix, Inc. is a pharmaceutical company, which engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders.It develops two products candidate: ZX008 and Relday.The company was founded by Stephen... 
More about the company
Surperformance© ratings of Zogenix, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ZOGENIX, INC.
2017 ZOGENIX, INC. : Termination of a Material Definitive Agreement (form 8-K)
2017 ZOGENIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2017 ZOGENIX, INC. : Other Events (form 8-K)
2017 ZOGENIX : Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 C..
2017 Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3..
2017 ZOGENIX : Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Synd..
2017 ZOGENIX, INC. : Other Events (form 8-K)
2017 ZOGENIX : to Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on ..
2017 ZOGENIX : Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Synd..
2017 Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Sy..
More news
Sector news : Bio Medical Devices
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Medical Devices
Latest Tweets
01/16Zogenix $ZGNX Receiving Somewhat Positive Press Coverage, Study Shows  
01/12$ZGNX - Zogenix #ZGNX Stock Rating Lowered by BidaskClub  
01/11Michael Smith: Rotherham sign Bury striker for undisclosed fee
1
01/06Somewhat Favorable News Coverage Somewhat Unlikely to Affect Zogenix $ZGNX St.. 
01/04Counsyl Appoints Ann Rhoads to Board of Directors: SOUTH SAN FRANCISCO, Calif.. 
More tweets
Qtime:142
News from SeekingAlpha
01/09 How I Beat The Market In 2017
01/08 Zogenix (ZGNX) Presents At LifeSci Advisors Corporate Access Event - Slidesho..
2017 Stocks to watch next week
2017 BIOTECH BONANZA : Biotech Stocks To Keep Shining In 2018
2017 YOUR DAILY PHARMA SCOOP : Ultragenyx Sells Voucher, Regeneron Announces Collabor..
Chart ZOGENIX, INC.
Duration : Period :
Zogenix, Inc. Technical Analysis Chart | ZGNX | US98978L2043 | 4-Traders
Technical analysis trends ZOGENIX, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 50,4 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Stephen J. Farr President, Chief Executive Officer & Director
Cam L. Garner Chairman
Michael P. Smith CFO, Secretary, Treasurer & Executive VP
Bradley S. Galer Chief Medical Officer & Executive Vice President
Roger L. Hawley Director
Sector and Competitors
1st jan.Capitalization (M$)
ZOGENIX, INC.-11.49%1 134
GILEAD SCIENCES14.10%105 754
VERTEX PHARMACEUTICALS4.76%39 951
REGENERON PHARMACEUTICALS-0.50%39 917
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC2.37%21 423